In the attached article, from The Economist, investors are hoping that medical psychedelics will be the new cannabis.
It briefly looks at how Ketamine and psilocybin (which gives mushrooms their magic) are being researched for their potential effects on psychiatric conditions such as depression, anxiety, and addiction.
Reference
The Economist. (2019) Medical Psychedelics: Shroom to Grow. The Economist. 16 October 2019.
Mental Health Matters 
Absolutely! The beautiful thing about Psilocybin is that its chemical bond is so similar to serotonin that it actually fits into those receptors. The difference between using shrooms and an anti-depressant is that the medication stop your body from absorbing some of the serotonin you body makes, so that it’s available to those receptors. If you barely produce Serotonin these meds arent going to do the trick. However, shrooms work like adding extra serotonin to you body to use.
LikeLike
What very good news. If indeed this turns out to be the case.
LikeLike